EVALUATION OF THE THERAPEUTIC EFFICACY OF THE DRUG SELENCIN IN COMBINED THERAPY OF ALOPECIA


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The article presents the results of the study of effectiveness of Selencin in the treatment of androgenetic alopecia and telogen effluvium involving 30 patients who received drug therapy (homeopathic medicine Selentsin, containing L-cysteine) and topical therapy (lotion based on biomimetic peptides) on skin of hairy part of the head. The study showed a high therapeutic efficacy of Selencin in the treatment of telogenic effluvium and androgenetic alopecia.

Texto integral

Acesso é fechado

Sobre autores

A. Kubanov

SBEI FPE “Russian Medical Academy of Postgraduate Education» of RMPH; FSBI “State Research Center of Dermatology and Cosmetology" of RMPH

Moscow

Yu. Galliamova

SBEI FPE “Russian Medical Academy of Postgraduate Education» of RMPH

Moscow

O. Selezneva

SBEI FPE “Russian Medical Academy of Postgraduate Education» of RMPH

Email: olselezneva83@gmail.com
postgraduate student att he Department of Dermatology, Cosmetology and Mycology Moscow

Bibliografia

  1. Werner B, Mulinari-Brenner F. Clinical and histological challenge in the differential diagnosis of diffuse alopecia: female androgenetic alopecia,telogen effluvium and alopecia areata-part II. An. Bras. Dermatol. 2012; 87(6):884-90.
  2. Headington J.T. Telogen effluvium. New concepts and review. Arch. Dermatol. 1993;129(3):356-63.
  3. Randall V.A. Hormonal regulation of hair follicles exhibits a biological paradox. Seminars in Cell & Developmental Biology 2007;18:274-85.
  4. Kaufman K.D. Androgens and alopecia. Mol. Cell. Endocrinol. 2002;198:89-95.
  5. Messenger A.G., de Berker D.A.R., Sinclair R.D. Chapter 66. Disorders of Hair. In: Rook's Textbook of Dermatology. 8th ed. Oxford, UK: Blackwell Science Publications. 2010. 66.1-66.16.
  6. Trueb R.M. Hair growth and disorders. Diffuse hair loss. In: Blume-Peytavi U., Tosti A., Whiting D.A., Trueb R., ed.; 1st edn. Berlin: Springer. 2008. 259-72.
  7. Sperling C. Hair and systemic disease. Dermatol. Clin. 2001;19:711-26.
  8. Соколовский Е.В. Облысение. Дифференциальный диагноз. Методы терапии. СПб., 2003. 176 с.
  9. Kligman A.M. Pathologic dynamics of human hair loss. I. Telogen effluvium. Arch. Dermatol. 1961;83:175-98.
  10. Fiedler V.C., Gray A.C. Chapter 10. Diffuse alopecia: telogen hair loss. In: Olsen EA, ed. Disorders of Hair Growth: Diagnosis and Treatment. 2nd ed. New York, NY: McGraw-Hill Publishing. 2003. 303-20.
  11. Bergfeld W.F. Chapter 9. Telogen effluvium. In: McMichael J, Hordin MK, eds. Hair and Scalp Diseases: Medical, Surgical, and Cosmetic Treatments. London, UK: Informa Health Care. 2008;119-36.
  12. Галлямова Ю.А, Верхогляд И.В., Аль-Хадж Хассан Халед, Амбарян Д.А. Нарушения микрогемодинамики кожи волосистой части головы у больных диффузной алопецией. Рос. журн. кожных и венерических болезней. 2010;3:52-4
  13. Chu T.W., Santos L., McElwee K.J. Biology of the hair follicle and mechanisms of nonscarring and scarring alopecia. Seminars in Cutaneous Medicine and Surgery. 2015;34(2):50-6.
  14. Вольф К., Голдсмит Л.А., Кац С.И., et al. Пер. с англ.; общ. ред. А.А. Кубановой. Дерматология Фицпатрика в клинической практике: 3 том. М., Лаборатория знаний. 2012.
  15. Ellis J.A., Sinclair R., Harrap S.B. Androgenetic alopecia: pathogenesis and potential for therapy. Exp. Rev. Mol. Med. 2002.
  16. Nyholt D.R., Gillespie N.A., Heath A.C., et al. Genetic basis of male pattern baldness. J. Invest. Dermatol. 2003;121:1561-63.
  17. Severi G., Sinclair R., Hopper J., English D.R., McCredie M.R., Boyle P., Giles G.G. Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors. Br. J. Dermatol. 2003;149:1207-13.
  18. Blume-Peytavi U., Blumeyer A., Tosti A., Finner A., Marmol V., Trakatelli M., Reygagne P., Messenger A. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br. J. Dermatol. 2011;164(1):5-15.
  19. Paus R., Olsen E.A., Messenger A.G. Hair growth disorders. In: Wolff K., Goldsmith L.A., Katz S.I., Gilchrest B.A., Paller As., Leffell D.J., ed. Fitzpatrick's Dermatology in General Medicine. 7th ed. USA; The McGraw-Hill Companies Inc. 2008. 753-77.
  20. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br. J. Dermatol. 1977; 97:247-54.
  21. Sawaya M.E., Shapiro J. Alopecia: unapproved treatments or indications. Clin. Dermatol. 2000;18:177-86. ства волос и волос в стадии анагена. Положительный эффект сохраняется в течение 6 месяцев. У больных телогенным выпадением волос, получивших комплексное лечение, показатели трихоскопии и фототрихограммы достигли нормы, что позволяет констатировать высокую эффективность данного лечения за счет воздействия на патогенетические звенья заболевания.
  22. Dawber R.P., Sonnex T., Ralfs I. Oral antiandrogen treatment of common baldness in women. Br. J. Dermatol. 1982;107(Suppl.):20.
  23. Ruchy J., Wanchai De-E. Potential targets in the discovery of new hair growth promoters for androgenic alopecia. Expert Opin. Ther. Targets. 2014;18(7).
  24. Mounsey A.L., Reed, S.W. Diagnosing and treating hair loss. American Family Physician, 2009;80(4):356-62.
  25. BlumeyerA., TostiA., MessengerA., Reygagne P., Del Marmol V., Spuls P.I., Trakatelli M., Finner A., Kiesewetter F., Trüeb R., Rzany B., Blume-Peytavi U. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and men. J. German Soc. Dermatol. 2011;(Suppl. 6):1-57.
  26. Vexiau P., Chaspoux C., Boudou P., Fiet J., Jouanique C., Hardy N., Reygagne P. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br. J. Dermatol. 2002;146:992-99.
  27. Sinclair R.D., Dawber R.D. Androgenetic alopecia in men and women. Clin. Dermatol. 2001;19:167-78.
  28. Lengg N., Heidecker B., Seifert B., et al. Dietary supplement increases anagen hair rate in women with telogen effluvium: results of a double-blind, placebo-controlled trial. Therapy. 2007;4(1):59-65.
  29. Böhlen P., Esch F., Baird A., Gospodarowicz D. Acidic fibroblast growth factor (FGF) from bovine brain: amino-terminal sequence and comparison with basic FGF. EMBO. J. 1985;4:1951-56.
  30. Kawano M., Komi-Kuramochi A., Asada M., Suzuki M., Oki J., Jiang J., Imamura T. Comprehensive analysis of FGF and FGFR expression in skin: fgf18 is highly expressed in hair follicles and capable of inducing anagen from telogen stage hair follicles. J. Invest. Dermatol. 2005;124:877-85.
  31. Kimura-Ueki M., Oda Y., Oki J., Komi-Kuramochi A., Honda E., Asada M., Suzuki M., Imamura T. Hair cycle resting phase is regulated by cyclic epithelial fgf18 signaling. J. Invest. Dermatol. 2012;132:1338-45.
  32. Ozeki M., Tabata Y. In vivo promoted growth of mice hair follicles by the controlled release of growth factors. Biomaterials. 2003; 24:2387-94.
  33. Tomita Y., Akiyama M., Shimizu H. PDGF isoforms induce and maintain anagen phase of murine hair follicles. J. Dermatol. Sci. 2006;43:105-15.
  34. Хавинсон В.Х., Кветная Т.В. Регуляторные пептиды и гомеостаз. Рос. химический журн. 2005;XLIX (1):112-17.
  35. Lupo M.P., Cole A.L. Cosmeceutical peptides. Dermatol. Ther. 2007;20(5):343-49.
  36. Аль-Хадж Хассан Халед. Оптимизация терапии диффузной алопеции с учетом нарушении микроциркуляции и обмена микроэлементов. Дисс. канд. мед. наук. М., 2010.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies